RxDoctor Payments Data

Gerardo Soto, MD

General Practice · Enid, OKNPI 1902197445

Payments from drug & device makers

$1,855in general payments, 2019–2025

Across 101 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$248
  • AbbVie$222
  • Amgen$221
  • Lilly USA, LLC$189
  • GSK$150
  • Johnson & Johnson$112
  • plus $713 from 17 others

What the payments were for

  • Food & beverage$1,65789%
  • Education$19811%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,855 in reported general payments places this provider in the 85th percentile of 1,086 general practice providers in Oklahoma.

See all general practice providers in Oklahoma

Medicare billing

Part B allowed, 2024
$8,818
Medicare patients
57
Services billed
630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide111$109,218
EliquisApixaban98$98,857
Humira PenAdalimumab12$96,695
JardianceEmpagliflozin68$53,560
FarxigaDapagliflozin Propanediol46$52,818
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$45,424
TrulicityDulaglutide21$39,686
LinzessLinaclotide54$34,435
JanuviaSitagliptin Phosphate28$28,135
XareltoRivaroxaban35$27,281
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen626$25,164
MounjaroTirzepatide22$23,744
TradjentaLinagliptin28$21,067
Xtampza ErOxycodone Myristate23$19,299
Combivent RespimatIpratropium/Albuterol Sulfate32$19,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$55$109,218111 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat$78$104,305145 claims
PfizerEliquis$37$98,85798 claims
AstraZenecaFarxiga, Symbicort$67$64,54086 claims
Lilly USA, LLCTrulicity, Mounjaro$189$63,43043 claims
GSKTrelegy Ellipta, Anoro Ellipta$150$62,83673 claims
AbbVieLinzess$222$34,43554 claims
Johnson & JohnsonXarelto$112$27,28135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,086 general practice providers in Oklahoma.

Other general practice in Enid

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →